|
1. The most commonly occurring hematologic cancer is...?
Leukemia
T-cell lymphoma
B-cell lymphoma
Follicular Cell Lymphoma
|
|
2. Of all new cases of NHL, what % are B-cell lymphomas...?
15
35
65
85
|
|
3.
15
35
65
90
|
|
4.
The 2nd most commonly occurring
hematologic cancer is...?:
Leukemia
T-cell lymphoma
B-cell lymphoma
Follicular
cell lymphoma
|
|
5.
Which ONE of the following is NOT a principle of
Radioimmunotherapy ...?
Targeted delivery of radiation
Greater exposure of tumors vs. surrounding organs by
virtue of the selectivity of the carrier antibody
Potential for one-time instantaneous exposure of
tumor cells
Anti-tumor mechanisms of the antibody
|
|
6. Bexxar and Zevalin are designed as...?:
A
single course of treatment
A monthly course each month for four months
Semi-annual treatments for three years
None
of the above
|
|
7. The unified therapy regimen for Bexxar and Zevalin
includes...:
Only an IV infusion of the radioactive antibody
Only an IV infusion of the non-radioactive antibody
An IV infusion of the radioactive antibody followed
by an IV infusion of the
non-radioactive antibody
An IV infusion of the non-radioactive antibody
followed by an IV infusion of the
radioactive antibody
|
|
8. Patient preparation for Zevalin therapy includes...:
a:
Thyroid blockage with non-radioactive iodine from
one day before Zevalin administration until 14 days after administration
b:
Acetaminophen and benadryl on a daily basis for 10
days
c:
Acetaminophen and benadryl on the day of drug
administration only
a and c only
|
|
9. Patient preparation for Bexxar therapy includes...?:
a:
Thyroid blockage with non-radioactive iodine from
one day before Zevalin administration until 14 days after administration
b: Acetaminophen and benadryl on a daily basis for 10
days
c:
Acetaminophen and benadryl on the day of drug
administration only
a and c only
|
|
10. Bexxar and Zevalin therapeutic doses are labeled
with _______ and _______, respectively...?
I-131 and In-111
I-125 and Cd-111
I-131 and Y-90
None
of the above
|
11.
Which one
of the following statements is true...?
Bexxar requires special radiation shielding because,
unlike Xevalin, the
beta-emitter used in Bexxar also emits many gamma-rays Zevalin requires special radiation shielding
because, unlike Bexxar, the
beta-emitter used in Zevalin also emits many gamma-rays
Both labeled antibodies are labeled with isotopes
that are pure alpha- emitters
Neither of the two isotopes is a pure beta-emitter
|
12.
What is the purpose of administering the unlabeled
antibody prior to administration of Bexxar or Zevalin...?
a: Reduces splenic uptake b:
Increases terminal half-life of the radiolabeled
antibody
a and c
None
of the above
|
13.
For Bexxar, the goal is to deliver a whole body dose
of...?
.75 cGy 7.5 cGy
75 cGy
750 cGy
|
14.
Following Bexxar therapy in patients with CD20
positive refractory or relapsed follicular, low grade, or relapsed NHL,
overall response rates ranged from...?
5-11 % 18-29%
47-68%
92-99%
|
15.
HAMA stands for...?
Health and Mental Attitude
Human Anti-Melanoma Antibody
Human Anti-Mouse Antibody
Herceptin Accelerated Modulated Antibody
|
16.
Which of the following render(s) a patient
ineligible for RIT Therapy?
a: Pregnant
or nursing women
b: Bone marrow involvement >10%
c:
Platelet count of 250,000
a
and c above
|
17.
Which one of the following statements is TRUE...?
The incidence of NHL has been increasing lately,
especially in young people The incidence of NHL has been decreasing lately,
especially in young people
The incidence of NHL has been increasing lately,
especially in older people
The incidence of NHL has been decreasing lately,
especially in older people
|
18.
Rituximab, the unlabeled antibody, has...?
a: been shown to be an effective treatment for certain
forms of NHL b:
been approved by the FDA for treatment for certain
forms of NHL
a
and b are correct
none
of the above
|
19.
When using Zevalin, the following protocol is
followed...?
5 mCi dosimetric dose of I-131 Zevalin; 50 mCi
therapeutic dose of I-131 Zevalin 5 mCi dosimetric dose of Y-90 Zevalin; 50 mCi
therapeutic dose of Y-90 Zevalin
5 mCi dosimetric dose of In-111 Zevalin; 32 mCi
therapeutic dose of Y-90 Zevalin
5 mCi dosimetric dose of I-131 Zevalin; 50 mCi
therapeutic dose of I-131 Zevalin
|
20.
The maximum dose of Zevalin that may be injected is
...?
3 mCi 32 mCi
75 mCi
100 mCi
|
